Study #NCI9673
NCI9673: Part A: A Multi-Institutional Phase II Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal (Original Protocol) Part B: Multi-Institutional Phase 2 Study of Nivolumab or Nivolumab in Combination with Ipilimumab in
MD Anderson Study Status
Not Accepting
Treatment Agent
Nivolumab, Ipilimumab
Description
This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and that has spread from where it first started (primary site) to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
Study phase:
Phase II
Physician name:
Van Morris
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-844-241-7617
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.